Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

The comparative disposition and metabolism of dolutegravir, a potent HIV-1 integrase inhibitor, in mice, rats, and monkeys.

Moss L, Wagner D, Kanaoka E, Olson K, Yueh YL, Bowers GD.

Xenobiotica. 2015 Jan;45(1):60-70. doi: 10.3109/00498254.2014.942409. Epub 2014 Jul 18.

PMID:
25034010
2.

In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.

Reese MJ, Savina PM, Generaux GT, Tracey H, Humphreys JE, Kanaoka E, Webster LO, Harmon KA, Clarke JD, Polli JW.

Drug Metab Dispos. 2013 Feb;41(2):353-61. doi: 10.1124/dmd.112.048918. Epub 2012 Nov 6.

PMID:
23132334
3.

Renoprotective action of a matrix metalloproteinase inhibitor in progressive mesangioproliferative nephritis.

Kuroda T, Masui M, Notoya M, Ito M, Tamura Y, Okamoto H, Kanaoka E, Shinosaki T.

Nephron Extra. 2012 Jan;2(1):133-46. doi: 10.1159/000338801. Epub 2012 May 26.

4.

Role of Na+/L-carnitine transporter (OCTN2) in renal handling of pivaloylcarnitine and valproylcarnitine formed during pivalic acid-containing prodrugs and valproic acid treatment.

Ohnishi S, Okamura N, Sakamoto S, Hasegawa H, Norikura R, Kanaoka E, Takahashi K, Horie K, Sakamoto K, Baba T.

Drug Metab Pharmacokinet. 2008;23(4):293-303.

5.

Continuous release of interleukin-2 from liposomal IL-2 (mixture of interleukin-2 and liposomes) after subcutaneous administration to mice.

Kanaoka E, Takahashi K, Yoshikawa T, Jizomoto H, Nishihara Y, Hirano K.

Drug Dev Ind Pharm. 2003 Nov;29(10):1149-53.

PMID:
14677775
6.

A new generic column switching system for quantitation in cassette dosing using LC/MS/MS.

Ohkawa T, Ishida Y, Kanaoka E, Takahashi K, Okabe H, Matsumoto T, Nakamoto S, Tamada J, Koike M, Yoshikawa T.

J Pharm Biomed Anal. 2003 Apr 10;31(6):1089-99.

PMID:
12667925
7.

A significant enhancement of therapeutic effect against hepatic metastases of M5076 in mice by a liposomal interleukin-2 (mixture).

Kanaoka E, Takahashi K, Yoshikawa T, Jizomoto H, Nishihara Y, Uchida N, Maekawa R, Hirano K.

J Control Release. 2002 Aug 21;82(2-3):183-7.

PMID:
12175736
8.

Microemulsion formulation for enhanced absorption of poorly soluble drugs. I. Prescription design.

Kawakami K, Yoshikawa T, Moroto Y, Kanaoka E, Takahashi K, Nishihara Y, Masuda K.

J Control Release. 2002 May 17;81(1-2):65-74.

PMID:
11992679
9.

A novel and simple type of liposome carrier for recombinant interleukin-2.

Kanaoka E, Takahashi K, Yoshikawa T, Jizomoto H, Nishihara Y, Hirano K.

J Pharm Pharmacol. 2001 Mar;53(3):295-302.

PMID:
11291744
10.

Stabilization of aerosolized IFN-gamma by liposomes.

Kanaoka E, Nagata S, Hirano K.

Int J Pharm. 1999 Oct 25;188(2):165-72.

PMID:
10518672
11.
12.

Supplemental Content

Loading ...
Support Center